Evolent Health, Inc. (NYSE:EVH) Stock Holdings Boosted by Wellington Management Group LLP

Wellington Management Group LLP grew its position in shares of Evolent Health, Inc. (NYSE:EVH - Free Report) by 12.8% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 12,595,459 shares of the technology company's stock after purchasing an additional 1,426,747 shares during the period. Wellington Management Group LLP owned approximately 10.83% of Evolent Health worth $356,200,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the company. Quarry LP purchased a new stake in Evolent Health during the 2nd quarter worth $32,000. Covestor Ltd grew its stake in shares of Evolent Health by 138.1% during the third quarter. Covestor Ltd now owns 1,424 shares of the technology company's stock valued at $40,000 after acquiring an additional 826 shares in the last quarter. GAMMA Investing LLC increased its position in shares of Evolent Health by 5,365.5% during the third quarter. GAMMA Investing LLC now owns 1,585 shares of the technology company's stock worth $45,000 after acquiring an additional 1,556 shares during the last quarter. Canada Pension Plan Investment Board purchased a new stake in shares of Evolent Health during the second quarter worth about $61,000. Finally, Quest Partners LLC acquired a new position in shares of Evolent Health in the second quarter worth about $87,000.

Evolent Health Stock Performance

Shares of NYSE:EVH traded down $0.10 during trading on Friday, reaching $11.15. 2,375,484 shares of the company's stock traded hands, compared to its average volume of 3,976,320. The stock has a market capitalization of $1.30 billion, a P/E ratio of -12.25 and a beta of 1.45. Evolent Health, Inc. has a 12 month low of $10.82 and a 12 month high of $35.00. The company has a 50 day moving average of $19.73 and a 200-day moving average of $22.93. The company has a debt-to-equity ratio of 0.58, a current ratio of 1.04 and a quick ratio of 1.04.

Analysts Set New Price Targets

EVH has been the subject of a number of recent analyst reports. Stephens lowered Evolent Health from an "overweight" rating to an "equal weight" rating and lowered their price objective for the company from $38.00 to $16.00 in a research note on Friday, November 8th. BTIG Research decreased their price target on shares of Evolent Health from $36.00 to $29.00 and set a "buy" rating for the company in a research report on Tuesday, December 3rd. Citigroup cut their price target on shares of Evolent Health from $33.00 to $21.00 and set a "buy" rating on the stock in a report on Wednesday, November 13th. Oppenheimer reduced their price objective on shares of Evolent Health from $34.00 to $28.00 and set an "outperform" rating on the stock in a research note on Monday, November 18th. Finally, JPMorgan Chase & Co. dropped their target price on shares of Evolent Health from $45.00 to $15.00 and set an "overweight" rating for the company in a research report on Friday, November 22nd. One analyst has rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Buy" and a consensus target price of $26.18.

About Evolent Health

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.